Saturday 17 October 2026
Export NSRX’s income statement to Excel — free account
Nasus Pharma Ltd.
NSRX Healthcare Drug Manufacturers General
Insiders bought in the last twelve months.
3.18
0.01
+0.32%
Follow NSRX
| Dec '25 | Dec '24 | Dec '23 | |
|---|---|---|---|
Current Ratio |
2.24 | 0.12 | 0.10 |
Net Debt/EBITDA |
0.26 | (1.38) | (1.96) |
Debt/Assets |
0.00% | 251.32% | 553.38% |
Debt/Equity |
0.00 | (0.56) | (0.65) |
Asset Turnover |
0.00 | 0.00 | — |
Operating CF/Net income |
0.84 | 0.43 | 0.98 |
Capex/Depreciation |
0.00 | — | — |
Interest Coverage |
62.87 | (37.17) | (23.41) |
| 2,637.84% | 43.72% | 0.00% | |
| (204.72%) | (263.91%) | 0.00% | |
ROIC |
(207.52%) | 0.00% | 0.00% |
Return on Tangible Assets |
(216.41%) | 44.12% | 27.68% |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% |
Free Cash Flow per Share |
(0.62) | (0.09) | (0.15) |
Cash per Share |
0.16 | 0.04 | 0.03 |
Shareholders Equity per Share |
0.35 | (0.46) | (0.55) |
Interest Debt per Share |
0.00 | 0.00 | 0.00 |
Book value per Share |
0.35 | (0.46) | (0.55) |
Free Cash Flow |
(4.93) | (0.66) | (1.03) |
Working Capital |
2.69 | (3.47) | (3.80) |
Capital Expenditures |
(0.01) | — | — |
Net Current Asset Value |
2.62 | (3.47) | (3.80) |
| Other line items | |||
Quick Ratio |
0.60 | 0.08 | 0.05 |
Depreciation/Fixed assets |
0.00 | — | — |
Cash ROIC |
(121.51%) | 60.51% | 91.06% |
Accounts Payable Turnover |
0.00 | 0.00 | — |
Average Days of Payables |
0.00 | 0.00 | 0.00 |
Revenue per Share |
0.00 | 0.00 | 0.00 |
Operating CF per Share |
(0.61) | (0.09) | (0.15) |
Capex per Share |
0.00 | 0.00 | 0.00 |
Average Payables |
0.74 | 0.65 | — |
Average Assets |
2.86 | 0.58 | — |
Average Common Equity |
(0.22) | (3.50) | — |
Capex to Sales |
0.00 | — | — |
Columns are period end dates